Hypoparathyroidism differential diagnosis: Difference between revisions
No edit summary |
|||
Line 48: | Line 48: | ||
*Normal [[urinary]] [[phosphate]] | *Normal [[urinary]] [[phosphate]] | ||
|- | |- | ||
| rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Pseudohypoparathyroidism''' | | rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Pseudohypoparathyroidism'''<ref name="pmid23076042">{{cite journal |vauthors=Levine MA |title=An update on the clinical and molecular characteristics of pseudohypoparathyroidism |journal=Curr Opin Endocrinol Diabetes Obes |volume=19 |issue=6 |pages=443–51 |year=2012 |pmid=23076042 |pmc=3679535 |doi=10.1097/MED.0b013e32835a255c |url=}}</ref><ref name="pmid21816789">{{cite journal |vauthors=Mantovani G |title=Clinical review: Pseudohypoparathyroidism: diagnosis and treatment |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=10 |pages=3020–30 |year=2011 |pmid=21816789 |doi=10.1210/jc.2011-1048 |url=}}</ref><ref name="pmid25891861">{{cite journal |vauthors=Lee S, Mannstadt M, Guo J, Kim SM, Yi HS, Khatri A, Dean T, Okazaki M, Gardella TJ, Jüppner H |title=A Homozygous [Cys25]PTH(1-84) Mutation That Impairs PTH/PTHrP Receptor Activation Defines a Novel Form of Hypoparathyroidism |journal=J. Bone Miner. Res. |volume=30 |issue=10 |pages=1803–13 |year=2015 |pmid=25891861 |pmc=4580526 |doi=10.1002/jbmr.2532 |url=}}</ref> | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 1a''' | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 1a''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Genetic defect causing end organ resistance to the action of parathyroid hormone (PTH) | *[[Genetic defect]] causing end organ resistance to the action of [[parathyroid hormone]] (PTH). | ||
*[[Heterozygous]] ''[[GNAS1|GNAS]]'' inactivating mutations that reduce expression or function of Gα<sub>s</sub> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | ||
Line 62: | Line 63: | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 1b''' | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 1b''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Genetic defect causing end organ resistance to the action of parathyroid hormone (PTH) | *[[Genetic defect]] causing end organ resistance to the action of [[parathyroid hormone]] (PTH). | ||
*[[Familial]]- [[heterozygous]] deletions in ''[[STX16|STX]]16'', NESP55, and/or AS exons or loss of [[methylation]] at ''[[GNAS1|GNAS]]'' | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | ||
Line 73: | Line 75: | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 1c''' | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 1c''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Genetic defect causing end organ resistance to the action of parathyroid hormone (PTH) | *[[Genetic defect]] causing end organ resistance to the action of [[parathyroid hormone]] (PTH). | ||
*[[Heterozygous]] ''[[GNAS1|GNAS]]'' inactivating mutations that reduce expression or function of Gα<sub>s</sub> | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | ||
Line 84: | Line 87: | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 2''' | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Type 2''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Genetic defect causing end organ resistance to the action of parathyroid hormone (PTH) | *[[Genetic defect]] causing end organ resistance to the action of [[parathyroid hormone]] (PTH). | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↑''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''↓''' | ||
Line 95: | Line 98: | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Pseudopseudohypoparathyroidism''' | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |'''Pseudopseudohypoparathyroidism''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Genetic defect causing end organ resistance to the action of parathyroid hormone (PTH) | *[[Genetic defect]] causing end organ resistance to the action of [[parathyroid hormone]] (PTH). | ||
*Combination of inactivating mutations of ''[[GNAS1]]'' and [[Albright's hereditary osteodystrophy|Albright's osteodystrophy]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal |
Revision as of 15:35, 3 October 2017
Hypoparathyroidism Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hypoparathyroidism differential diagnosis On the Web |
American Roentgen Ray Society Images of Hypoparathyroidism differential diagnosis |
Risk calculators and risk factors for Hypoparathyroidism differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Hypoparathyroidism should be differentiated from other causes of hypocalcemia. Causes of hypocalcemia other than hypoparathyroidism include pseudohypoparathyroidism, hypomagnesemia, hypovitaminosis D, chronic kidney disease, and relative hypocalcemia due to hypoalbuminemia.
Differentiating Hypoparathyroidism from other Diseases
Hypoparathyroidism should be differentiated from other causes of hypocalcemia. Causes of hypocalcemia other than hypoparathyroidism include:
- Pseudohypoparathyroidism
- Pseudohypoparathyroidism type 1
- Pseudohypoparathyroidism type 1a
- Pseudohypoparathyroidism type 1b
- Pseudohypoparathyroidism type 1c
- Pseudopseudohypoparathyroidism
- Pseudohypoparathyroidism type 2
- Pseudohypoparathyroidism type 1
- Hypomagnesemia
- Hypovitaminosis D
- Chronic kidney disease
- Hypoalbuminemia (relative hypocalcemia).
Differential diagnosis of hyperparathyroidism on the basis of hypocalcemia | |||||||
---|---|---|---|---|---|---|---|
Disorders | Mechanism of hypocalcemia | Laboratory findings | |||||
Serum PTH | Serum Calcium | Serum Phosphate | Other findings | ||||
Hypoparathyroidism |
|
↓ | ↓ | ↑ |
| ||
Pseudohypoparathyroidism[1][2][3] | Type 1a |
|
↑ | ↓ | ↑ | ||
Type 1b |
|
↑ | ↓ | ↑ | |||
Type 1c |
|
↑ | ↓ | ↑ | |||
Type 2 |
|
↑ | ↓ | ↑ |
| ||
Pseudopseudohypoparathyroidism |
|
Normal | Normal | Normal | -- | ||
Hypomagnesemia[4][5] |
|
Inappropriately ↓ | Normal/↓ | -- | |||
Hypoalbuminemia |
|
-- | ↓ | -- |
| ||
Hypovitaminosis D |
|
↑ | ↓ | ↓/Low-normal | |||
Chronic kidney disease |
|
↑ | ↓/Normal | ↑ |
References
- ↑ Levine MA (2012). "An update on the clinical and molecular characteristics of pseudohypoparathyroidism". Curr Opin Endocrinol Diabetes Obes. 19 (6): 443–51. doi:10.1097/MED.0b013e32835a255c. PMC 3679535. PMID 23076042.
- ↑ Mantovani G (2011). "Clinical review: Pseudohypoparathyroidism: diagnosis and treatment". J. Clin. Endocrinol. Metab. 96 (10): 3020–30. doi:10.1210/jc.2011-1048. PMID 21816789.
- ↑ Lee S, Mannstadt M, Guo J, Kim SM, Yi HS, Khatri A, Dean T, Okazaki M, Gardella TJ, Jüppner H (2015). "A Homozygous [Cys25]PTH(1-84) Mutation That Impairs PTH/PTHrP Receptor Activation Defines a Novel Form of Hypoparathyroidism". J. Bone Miner. Res. 30 (10): 1803–13. doi:10.1002/jbmr.2532. PMC 4580526. PMID 25891861.
- ↑ Jahnen-Dechent W, Ketteler M (2012). "Magnesium basics". Clin Kidney J. 5 (Suppl 1): i3–i14. doi:10.1093/ndtplus/sfr163. PMC 4455825. PMID 26069819.
- ↑ Freitag JJ, Martin KJ, Conrades MB, Bellorin-Font E, Teitelbaum S, Klahr S, Slatopolsky E (1979). "Evidence for skeletal resistance to parathyroid hormone in magnesium deficiency. Studies in isolated perfused bone". J. Clin. Invest. 64 (5): 1238–44. doi:10.1172/JCI109578. PMC 371269. PMID 227929.